Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and function impairment in subjects with cardiovascular disease

Journal of Clinical Investigation

Volumn 114, Issue 4, 2004, Pages 529-541

  Zheng, Lemin ^a,b   Nukuna, Benedicta ^a   Brennan, Marie Luise ^a   Sun, Mingjiang ^a   Goormastic, Marlene ^a   Settle, Megan ^a   Schmitt, Dave ^a   Fu, Xiaoming ^a   Thomson, Leonor ^c,e   Fox, Paul L ^a,d   Ischiropoulos, Harry ^c   Smith, Jonathan D ^a,d   Kinter, Michael ^a,b,d   Hazen, Stanley L ^a,b,d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND STATE UNIVERSITY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN; MYELOPEROXIDASE; ABC TRANSPORTER; ABC TRANSPORTER A1; CHOLESTEROL; DRUG DERIVATIVE; NITRO DERIVATIVE; PEROXIDASE; TYROSINE;

ARTICLE; ATHEROMA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CATALYSIS; CHLORINATION; CHOLESTEROL BLOOD LEVEL; ENZYME BINDING; HUMAN; IMMUNOPRECIPITATION; NITRATION; OXIDATION; PRIORITY JOURNAL; AGED; ANIMAL; AORTA; ARTERIOSCLEROSIS; BLOOD; CELL LINE; CHEMISTRY; COHORT ANALYSIS; COMPARATIVE STUDY; FEMALE; FEMORAL ARTERY; MACROPHAGE; MALE; METABOLISM; MIDDLE AGED; MOUSE; OXIDATION REDUCTION REACTION; PATHOLOGY; PATHOPHYSIOLOGY; WESTERN BLOTTING;

AGED; ANIMALS; AORTA; APOLIPOPROTEIN A-I; ARTERIOSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; BLOTTING, WESTERN; CARDIOVASCULAR DISEASES; CATALYSIS; CELL LINE; CHOLESTEROL; COHORT STUDIES; FEMALE; FEMORAL ARTERY; HUMANS; LIPOPROTEINS, HDL; MACROPHAGES; MALE; MICE; MIDDLE AGED; NITRO COMPOUNDS; OXIDATION-REDUCTION; PEROXIDASE; TYROSINE;

EID: 4344577056     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200421109     Document Type: Article

References (97)

1. Chisolm, G.M., and Steinberg, D. 2000. The oxidative modification hypothesis of atherogenesis: an overview. Free Radic. Biol. Med. 28:1815-1826.
2. Lusis, A.J. 2000. Atherosclerosis. Nature. 407:233-241.
3. Navab, M., et al. 2002. Oxidized lipids as mediators of coronary heart disease. Curr. Opin. Lipidol. 13:363-372.
4. Podrez, E.A., Abu-Soud, H.M., and Hazen, S.L. 2000. Myeloperoxidase- generated oxidants and atherosclerosis. Free Radic. Biol. Med. 28:1717-1725.
5. Heinecke, J.W. 2003. Oxidative stress: new approaches to diagnosis and prognosis in atherosclerosis. Am. J. Cardiol. 91:12A-16A.
6. Beckman, J.S., and Koppenol, W.H. 1996. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am. J. Physiol. 271:C1424-C1437.
7. Beckman, J.S., Chen, J., Ischiropoulos, H., and Crow, J.P. 1994. Oxidative chemistry of peroxynicrite. Methods Enzymol. 233:229-240.
8. Leeuwenburgh, C., et al. 1997. Reactive nitrogen intermediates promote low density lipoprotein oxidation in human atherosclerotic intima. J. Biol. Chem. 272:1433-1436.
9. Podrez, E.A., Schmitt, D., Hoff, H.F., and Hazen, S.L. 1999. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J. Clin. Invest. 103:1547-1560.
10. Shishehbor, M.H., et al. 2003. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA 289:1675-1680.
11. Kinlay, S., Libby, P., and Ganz, P. 2001. Endothelial function and coronary artery disease. Curr. Opin. Lipidol. 12:383-389.
12. Moncada, S. 1999. Nitric oxide: discovery and impact on clinical medicine. J. R. Soc. Med. 92:164-169.
13. Ignarro, L.J., Napoli, C., and Loscalzo, J. 2002. Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circ. Res. 90:21-28.
14. Graham, A., et al. 1993. Peroxynitrite modification of low-density lipoprotein leads to recognition by the macrophage scavenger receptor. FEBS Lett. 330:181-185.
15. MacMillan-Crow, L.A., Crow, J.P., Kerby, J.D., Beckman, J.S., and Thompson, J.A. 1996. Nitration and inactivation of manganese superoxide dismutase in chronic rejection of human renal allografts. Proc. Natl. Acad. Sci. U. S. A. 93:11853-11858.
16. Hazen, S.L., Hsu, F.F., Gaut, J.P., Crowley, J.R., and Heinecke, J.W. 1999. Modification of proteins and lipids by myeloperoxidase. Methods Enzymol. 300:88-105.
17. Brennan, M.L., et al. 2002. A tale of two controversies: defining both the role of peroxidases in nitrotyrosine formation in vivo using eosinophil peroxidase and myeloperoxidase-deficient mice, and the nature of peroxidase-generated reactive ni trogen species. J. Biol. Chem. 277:17415-17427.
18. van der Vliet, A., Eiserich, J.P., Halliwell, B., and Cross, C.E. 1997. Formation of reactive nitrogen species during peroxidase-catalyzed oxidation of nitrite. A potential additional mechanism of nitric oxide-dependent toxicity. J. Biol. Chem. 272:7617-7625.
19. Eiserich J.P., et al. 1998. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature. 391:393-397.
20. Wu, W., Chen, Y., and Hazen, S.L. 1999. Eosinophil peroxidase nitrates protein tyrosyl residues. Implications for oxidative damage by nitrating intermediates in eosinophilic inflammatory disorders. J. Biol. Chem. 274:25933-25944.
21. Beckmann, J.S., et al. 1994. Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry. Biol. Chem. Hoppe-Seyler. 375:81-88.
22. Shishehbor, M.H., et al. 2003. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation. 108:426-431.
23. Abu-Soud, H.M., and Hazen, S.L. 2000. Nitric oxide is a physiological substrate for mammalian peroxidases. J. Biol. Chem. 275:37524-37532.
24. Burner, U., Furtmuller, P.G., Kettle, A.J., Koppenol, W.H., and Obinger, C. 2000. Mechanism of reaction of myeloperoxidase with nitrite. J. Biol. Chem. 275:20597-20601.
25. Zhang, R., et al. 2002. Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J. Biol. Chem. 277:46116-46122.
26. Baldus, S., et al. 2001. Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration. J. Clin. Invest. 108:1759-1770. doi:10.1172/ JCI200112617.
27. Gaut, J.P., et al. 2002. Myeloperoxidase produces nitrating oxidants in vivo. J. Clin. Invest. 109:1311-1319. doi:10.1172/JCI200215021.
28. Daugherty, A., Dunn, J.L., Rateri, D.L., and Heinecke, J.W. 1994. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J. Clin. Invest. 94:437-444.
29. Sugiyama, S., et al. 2001. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am. J. Pathol. 158:879-891.
30. Hazen, S.L., Gaut, J.P., Crowley, J.R., Hsu, F.F., and Heinecke, J.W. 2000. Elevated levels of protein-bound p-hydroxyphenylacet aldehyde, an amino-acid-derived aldehyde generated by myeloperoxidase, are present in human fatty streaks, intermediate lesions and advanced atherosclerotic lesions. Biochem. J. 3:693-699.
31. Thukkani, A. K., et al. 2003. Identification of alphachloro fatty aldehydes and unsaturated. Circulation. 108:3128-3133.
32. Zhang, R., et al. 2001. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 286:2136-2142.
33. Brennan, M.L., et al. 2003. Prognostic value of myeloperoxidase in patients with chest pain. N. Engl. J. Med. 349:1595-1604.
34. Baldus, S., et al. 2003. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 108:1440-1445.
35. Carr, A.C., Myzak, M.C., Stocker, R., McCall, M.R., and Frei, B. 2000. Myeloperoxidase binds to low-density lipoprotein: potential implications for atherosclerosis. FEBS Lett. 487:176-180.
36. Yang, C.Y., et al. 1999. Selective modification of apoB-100 in the oxidation of low density lipoproteins by myeloperoxidase in vitro. J. Lipid Res. 40:686-698.
37. Hazen, S.L., and Heinecke, J.W. 1997. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J. Clin. Invest. 99:2075-2081.
38. Brennan, M.L., et al. 2001. Increased atherosclerosis in myeloperoxidase-deficient mice. J. Clin. Invest. 107:419-430.
39. Zhang, Z., and Smith, D.L. 1993. Determination of amide hydrogen exchange by mass spectrometry: a new tool for protein structure elucidation. Protein Sci. 2:522-531.
40. Woods, V.L., Jr., and Hamuro, Y. 2001. High resolution, high-throughput amide deuterium exchangemass spectrometry (DXMS) determination of protein binding site structure and dynamics: utility in pharmaceutical design. J. Cell. Biochem. Suppl. 37:89-98.
41. Remaley, A.T., et al. 1997. Decreased reverse cholesterol transport from Tangier disease fibroblasts. Acceptor specificity and effect of brefeldin on lipid efflux. Artenoscler. Thromb. Vasc. Biol. 17:1813-1821.
42. Takahashi, Y., et al. 2000. Identification of cAMP analogue inducible genes in RAW264 macrophages. Biochim. Biophys. Acta. 1492:385-394.
43. Chen, W., Silver, D.L., Smith, J.D., and Tall, A.R. 2000. Scavenger receptor-BI inhibits ATP-binding cassette transporter 1-mediated cholesterol efflux in macrophages. J. Biol. Chem. 275:30794-30800.
44. Smith, J.D., et al. 1996. Cyclic AMP induces apolipoprotein E binding activity and promotes cholesterol efflux from a macrophage cell line to apolipoprotein acceptors. J. Biol. Chem. 271:30647-30655.
45. Takahashi, Y., and Smith, J.D. 1999. Cholesterol efflux to apolipoprotein AI involves endocytosis and resecretion in a calcium-dependent pathway. Proc. Natl. Acad. Sci. U. S. A. 96:11358-11363.
46. Boullier, A., et al. 2001. Scavenger receptors, oxidized LDL, and atherosclerosis. Ann. N. Y. Acad. Sci. 947:214-222.
47. Navab, M., et al. 2001. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler. Thromb. Vasc. Biol. 21:481-488.
48. Ansell, B.J., et al. 2003. Inflammatory/antiinflammatory properties of high-density lipoprotein. Circulation. 108:2751-2756.
49. Navab, M., et al. 2000. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J. Lipid Res. 41:1481-1494.
50. Navab, M., Van Lenten, B.J., Reddy, S.T., and Fogelman, A.M. 2001. High-density lipoprotein and the dynamics of atherosclerotic lesions. Circulation. 104:2386-2387.
51. Navab, M., et al. 2001. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J. Lipid Res. 42:1308-1317.
52. Nagano, Y., Arai, H., and Kita, T. 1991. High density lipoprotein loses its effect to stimulate efflux of cholesterol from foam cells after oxidative modification. Proc. Natl. Acad. Sci. U. S. A. 88:6457-6461.
53. Panzenboeck, U., et al. 1997. Effects of reagent and enzymatically generated hypochlorite on physico-chemical and metabolic properties of high density lipoproteins. J. Biol. Chem. 272:29711-29720.
54. Bergt, C., et al. 2001. Human neutrophils employ the myeloperoxidase/ hydrogen peroxide/chloride system to oxidatively damage apolipoprotein A-I. Eur. J. Biochem. 268:3523-3531.
55. Graham, A., Vinogradov, D.V., and Owen, J.S. 1998. Effects of peroxynitrite on plasma components of the reverse cholesterol transport pathway. FEBS Lett. 431:327-332.
56. Wang, W.Q., Merriam, D.L., Moses, A.S., and Francis, G.A. 1998. Enhanced cholesterol efflux by tyrosyl radical-oxidized high density lipoprotein is mediated by apolipoprotein AI-AII heterodimers. J. Biol. Chem. 273:17391-17398.
57. Panzenbock, U., Kritharides, L., Raftery, M., Rye, K.A., and Stocker, R. 2000. Oxidation of methionine residues to methionine sulfoxides does not decrease potential antiatherogenic properties of apolipoprotein A-I. J. Biol. Chem. 275:19536-19544.
58. Marsche, G., et al. 2002. Hypochlorite-modified high density lipoprotein, a high affinity ligand to scavenger receptor class B, type I, impairs high density lipoprotein-dependent selective lipid uptake and reverse cholesterol transport. J. Biol. Chem. 277:32172-32179.
59. Pryor, W.A. 2000. Vitamin E and heart disease: basic science to clinical intervention trials. Free Radic. Biol. Med. 28:141-164.
60. Steinberg, D., and Witztum, J.L. 2002. Is the oxidative modification hypothesis to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation. 105:2107-2111.
61. Vivekananthan, D.P., Penn, M.S., Sapp, S.K., Hsu, A., and Topol, E.J. 2003. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet. 361:2017-2023.
62. Hazell, L.J., and Stocker, R. 1997. Alpha-tocopherol does not inhibit hypochlorite-induced oxidation of apolipoprotein B-100 of low-density lipoprotein. FEBS Lett. 414:541-544.
63. Savenkova, M.L., Mueller, D.M., and Heinecke, J. W. 1994. Tyrosyl radical generated by myeloperoxidase is a physiological catalyst for the initiation of lipid peroxidation in low density lipoprotein. J. Biol. Chem. 269:20394-20400.
64. Rubbo, H., et al. 2000. Nitric oxide reaction with lipid peroxyl radicals spares alpha-tocopherol during lipid peroxidation. Greater oxidant protection from the pair nitric oxide/alpha-tocopherol than alpha-tocopherol/ascorbate. J. Biol. Chem. 275:10812-10818.
65. Upston, J.M., Terentis, A.C., and Stocker, R. 1999. Tocopherol-mediated peroxidation of lipoptoteins: implications for vitamin E as a potential antiatherogenic supplement. FASEB J. 13:977-994.
66. Lee, S.H., Oe, T., and Blair, I.A. 2001. Vitamin C-induced decomposition of lipid hydro peroxides to endogenous genotoxins. Science. 292:2083-2086.
67. Meagher, E.A., Barry, O.P., Lawson, J.A., Rokach, J., and FitzGerald, G.A. 2001. Effects of vitamin E on lipid peroxidation in healthy persons. JAMA. 285:1178-1182.
68. Van Lenten, B.J., Navab, M., Shih, D., Fogelman, A.M., and Lusis, A.J. 2001. The role of high-density lipoproteins in oxidation and inflammation. Trends Cardiovasc. Med. 11:155-161.
69. Nofer, J.R., et al. 2002. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis. 161:1-16.
70. Plump, A.S., Scott, C.J., and Breslow, J.L. 1994. Human apolipoprotein A-I gene expression increases high densitylipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. U. S. A. 91:9607-9611.
71. Nissen, S.E., et al. 2003. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 290:2292-2300.
72. Francis, G.A., Knopp, R.H., and Oram, J.F. 1995. Defective removal of cellular cholesterol and phospholipids by apolipoprotein A-I in Tangier disease. J. Clin. Invest. 96:78-87.
73. Brooks-Wilson, A., et al. 1999. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat. Genet. 22:336-345.
74. Bodzioch, M., et al. 1999. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat. Genet. 22:347-351.
75. Rust, S., et al. 1999. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat. Genet. 22:352-355.
76. Lawn, R.M., et al. 1999. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J. Clin. Invest. 104:25-31.
77. Singaraja, R.R., et al. 2002. Increased ABCA1 activity protects against atherosclerosis. J. Clin. Invest. 110:35-42. doi:10.1172/JCI200215748.
78. Aiello, R.J., et al. 2002. Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages. Arterioscler. Thromb. Vasc. Biol. 22:630-637.
79. Kutter, D., et al. 2000. Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit? Acta Haematol. 104:10-15.
80. Nikpoor, B., Turecki, G., Fournier, C., Theroux, P., and Rouleau, G.A. 2001. A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am. Heart J. 142:336-339.
81. Pecoits-Filho, R., et al. 2003. A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int. Suppl. 84:172-176.
82. Asselbergs, F.W., Reynolds, W.F., Cohen-Tervaert, J.W., Jessurun, G.A., and Tio, R.A. 2004. Myeloperoxidase polymorphism related to cardiovascular events in coronary artery disease. Am. J. Med. 116:429-430.
83. Vita, J.A., et al. 2004. Serum myeloperoxidase levels independently predict endothelial dysfunction: in vivo support that myeloperoxidase acts as a catalytic sink for nitric oxide. Circulation. In press.
84. Markwell, M.A., Haas, S.M., Bieber, L.L., and Tolbert, N.E. 1978. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal. Biochem. 87:206-210.
85. Nelson, D.P., and Kiesow, L.A. 1972. Enthalpy of decomposition of hydrogen peroxide by catalase at 25 degrees C (with molar extinction coefficients of H 2 O 2 solutions in the UV). Anal. Biochem. 49:474-478.
86. Rakita, R.M., Michel, B.R., and Rosen, H. 1990. Differential inactivation of Escherichia coli membrane dehydrogenases by a myeloperoxidase-mediated antimicrobial system. Biochemistry. 29:1075-1080.
87. Wever, R., Plat, H., and Hamers, M.N. 1981. Human eosinophil peroxidase: a novel isolation procedure, spectral properties and chlorinating activity. FEBS Lett. 123:327-331.
88. van Dalen, C.J., Whitehouse, M.W., Winterbourn, C.C., and Kettle, A.J. 1997. Thiocyanate and chloride as competing substrates for myeloperoxidase. Biochem. J. 327:487-492.
89. Agner, K. 1972. Biological effects of hyperchlorous acid formed by "MPO" peroxidation in the presence of chloride ions. In Structure and function of oxidation-reduction enzymes. 1st edition. A. Akeson and A. Ehrenberg, editors. Pergamon Press. Tatrytown, New York, USA. 329-335.
90. Hatch, F.T. 1968. Practical methods for plasma lipoprotein analysis. Adv. Lipid Res. 6:1-68.
91. Goldstein, J.L., Ho, Y.K., Basu, S.K., and Brown, M.S. 1979. Binding site on mactophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc. Natl. Acad. Sci. U. S. A. 76:333-337.
92. MacPherson, J.C., et al. 2001. Eosinophils are a major source of nitric oxide-derived oxidants in severe asthma: characterization of pathways available to eosinophils for generating reactive nitrogen species. J. Immunol. 166:5763-5772.
93. Steinbrecher, U.P., and Lougheed, M. 1992. Scavenger receptor-independent stimulation of cholesterol esterification in macrophages by low density lipoprotein extracted from human aortic intima. Arterioscler. Thromb. 12:608-625.
94. Krul, E.S., Tang, J., Kettler, T.S., Clouse, R.E., and Schonfeld, G. 1992. Lengths of truncated forms of apolipoprotein B (apoB) determine their intestinal production. Biochem. Biophys. Res. Commun. 189:1069-1076.
95. Laemmli, U.K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:680-685.
96. Kinter, M., and Sherman, N. 2000. Protein sequencing and identification using tandem mass spectrometry. John Wiley & Sons Inc. New York, New York, USA. 166-206.
97. Willard, B.B., Ruse, C.I., Keightley, J.A., Bond, M., and Kinter, M. 2003. Site-specific quantitation of protein nitration using liquid chromatography/tandem mass spectrometry. Anal. Chem. 75:2370-2376.